UNICANCER
Bevacizumab plus chemotherapy improves response rates and prolongs PFS when used as first- and second-line therapy for advanced breast cancer. However, bevacizumab has not improved OS in the individual studies currently reported. In Europe, EMA has maintained its indication associated with weekly paclitaxel in first line metastatic breast cancer and more recently with capecitabine based on RIBBON 1 trial's results. The identification of patient subsets that receive the most clinical benefit would enable more specific treatment administration of bevacizumab and allow patients unlikely to benefit the opportunity to seek other treatment modalities. Unfortunately, despite efforts to identify patient subsets with a differential benefit from bevacizumab, no validated biomarkers have been defined. The Avastin cohort is a unique opportunity to investigate various biological and imaging parameters which could be related to clinical benefit of the combination of bevacizumab and weekly paclitaxel in first line metastatic breast cancer in a homogeneously treated population in French cancer centers. This trial will gather the expertise of several translational research platforms of different cancer centers from the UNICANCER consortium.
Metastatic
Breast Cancer
Bevacizumab
paclitaxel
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 510 participants |
Official Title : | Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer |
Actual Study Start Date : | 2012-06 |
Estimated Primary Completion Date : | 2022-06 |
Estimated Study Completion Date : | 2022-12 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Bergonie Institute
Bordeaux, France,
Not yet recruiting
Centre Francois Baclesse
Caen, France,
Not yet recruiting
Jean Perrin Center
Clermont Ferrand, France,
Not yet recruiting
Georges Francois Leclerc Center
Dijon, France,
Not yet recruiting
CHU Grenoble
Grenoble, France,
Not yet recruiting
Leon Berard Center
Lyon, France,
Not yet recruiting
European Hospital
Marseille, France,
Not yet recruiting
Paoli Calmettes Institute
Marseille, France,
Not yet recruiting
Val d'Aurelle Center
Montpellier, France,
Not yet recruiting
Catherine Center of Siena
Nantes, France,
Not yet recruiting
Antoine Lacassagne Center
Nice, France,
Not yet recruiting
Curie Institute
Paris, France,
Not yet recruiting
Institut Jean Godinot
Reims, France,
Not yet recruiting
Hospital Center
Roanne, France,
Not yet recruiting
Curie Institute
Saint Cloud, France,
Not yet recruiting
Centre Paul Strauss
Strasbourg, France,
Not yet recruiting
Institut Claudius Regaud
Toulouse, France,
Not yet recruiting
Alexis Vautrin Center
Vandoeuvre les Nancy, France,
Not yet recruiting
Gustave Roussy Institute
Villejuif, France,